We are live on
!
Find out more
HA
HC Advisors Portfolio holdings
AUM
$149M
1-Year Est. Return
17.72%
This Fund
S&P 500
This Quarter
Est. Return
+4.58%
1 Year Est. Return
+17.72%
3 Year Est. Return
+55.19%
5 Year Est. Return
+59.33%
10 Year Est. Return
–
AUM
$155M
AUM Growth
+$8.44M
(+5.8%)
Cap. Flow
+$3.22M
Cap. Flow
% of AUM
2.08%
Top 10 Holdings %
Top 10 Hldgs %
63.18%
Holding
102
New
15
Increased
35
Reduced
19
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bank of America
BAC
|
+$1.22M |
| 2 |
JPMorgan Chase
JPM
|
+$1.1M |
| 3 |
First Trust Morningstar Dividend Leaders Index Fund
FDL
|
+$1.08M |
| 4 |
Schwab US Dividend Equity ETF
SCHD
|
+$1.01M |
| 5 |
Verizon
VZ
|
+$661K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$921K |
| 2 |
Sarepta Therapeutics
SRPT
|
+$730K |
| 3 |
TG Therapeutics
TGTX
|
+$668K |
| 4 |
Cytokinetics
CYTK
|
+$442K |
| 5 |
Cogent Biosciences
COGT
|
+$353K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 2.81% |
| 2 | Technology | 2.61% |
| 3 | Healthcare | 2.33% |
| 4 | Consumer Discretionary | 1.47% |
| 5 | Communication Services | 1.43% |
Similar funds
ZC
LGM
SWM
AWF
AIA
TWM
E
GWA
HC Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, HC Advisors held 102 positions worth $155M, up 5.8% from $146M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
HC Advisors's Q1 2021 filing shows 15 new, 35 increased, 19 reduced and 13 closed positions. Its largest new stake was Verizon: 11,714 shares worth $681K. The largest sale was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $921K.
By sector, the portfolio is most concentrated in Financials at 2.8% of assets, up from 0.93% a quarter earlier, followed by Technology and Healthcare.
- HC Advisors's largest Q1 2021 buy was Verizon: 11,714 shares worth $681K.
- HC Advisors added most to Bank of America in Q1 2021, an estimated $1.22M increase.
- HC Advisors's biggest Q1 2021 reduction was Cytokinetics, cutting an estimated $442K.
- HC Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021, selling an estimated $921K.
- HC Advisors's ten largest holdings make up 63% of its $155M portfolio in Q1 2021.
- HC Advisors opened 15 new positions and closed 13 in Q1 2021.
- HC Advisors's portfolio value rose 5.8% quarter-over-quarter to $155M.
Based on HC Advisors's 13F filing for Q1 2021, filed 7 May 2021.